Clinical trials: Papillary Thyroid Cancer, active
Thyroid Cancer Stage I
Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer
This is a prospective observational study. 1. In the first part of the study, consenting eligible adult patients with low risk papillary thyroid cancer that is confined to the thyroid, are provided verbal and written information…
- Trial name
- AS-PTC (NCT03271892)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma
Decision Aid Efficacy in Low Risk Thyroid Cancer
Low-risk thyroid cancer grows very slowly. More than 99% of patients with this cancer survive for at least 5 years. There are 3 main treatment options: remove the whole thyroid, remove just the part of the thyroid with the cancer…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma, Papillary Thyroid Carcinoma
- Trial name
- NCT07536412
- Testing
- Decision Aid
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Maryland, Baltimore
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Thyroid Cancer, Papillary
Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma
This study aims to investigate the efficacy and prognosis of ultrasound-guided and gene-based microwave ablation (MWA) versus surgical treatment in patients with low-risk papillary thyroid carcinoma (PTC).
- Trial name
- NCT06725576
- Testing
- Ablation
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer
Studies on Tumors of the Thyroid
Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid…
- Conditions
- Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer, Follicular Thyroid Cancer, Thyroid Cancer
- Trial name
- NCT00001160
- Testing
- 68-Gallium Dotatate
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
This study measures circulating immune-signaling molecules before thyroid surgery to determine whether they differ between patients whose thyroid nodule proves to be a differentiated thyroid carcinoma and patients whose nodule…
- Conditions
- Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma, Thyroid Cancer, Thyroid Nodule
- Trial name
- THINC (NCT07907432)
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Marmara University
Thyroid Cancer, Thyroid Neoplasms
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.
- Trial name
- IoN (NCT01398085)
- Testing
- I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation
- Where
- 36 sites in United Kingdom
- Volunteers
- 504 people
- Sponsor
- University College, London
Thyroid Cancer
Selective Neck Dissection Versus Modified Neck Dissection in PTC
This study is a phase III, randomized controlled, open label non inferiority study. Patients who meet the inclusion criteria are randomly assigned 1:1 to either the experimental group (selective neck dissection) or the control…
- Trial name
- NCT06554652
- Testing
- Lymph node tracer navigated selective neck dissection, Modified neck dissection
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Papillary Thyroid Cancer, Pediatric Cancer
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females.
- Conditions
- Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT05024929
- Testing
- Whole body scan
- Where
- 9 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Papillary Thyroid Carcinoma
Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy in clinical practice, accounting for approximately 85% of all thyroid malignancies.
- Trial name
- NCT07299318
- Testing
- not intervention
- Where
- China
- Volunteers
- 3,200 people
- Sponsor
- West China Hospital
Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm, Melanoma, Thyroid Gland Follicular Carcinoma
- Trial name
- NCT07529080
- Testing
- Internet-Based Intervention, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- University of Michigan Rogel Cancer Center
PTC, I-131
The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma
Clinincal data and pathological specimens from patients who had undergone at least one radioactive iodine-131 (^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were…
- Conditions
- PTC, I-131, Trop2
- Trial name
- ZL2025 (NCT07314255)
- Testing
- radioiodine-131 therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Papillary Thyroid Cancer
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
The purpose of this study is to determine whether results from a fine needle biopsy are the same as results from a larger sample that is acquired from the surgical pathology using the Thyroid GuidePx® test in patients with…
- Trial name
- NCT06133374
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- University of Calgary
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Thyroid Cancer, Papillary Thyroid Carcinoma
Active Surveillance for Low-risk Papillary Thyroid Carcinoma
This is a multi-center, non-randomized, prospective observational cohort study aimed at establishing a cohort of low-risk papillary thyroid cancer patients with a maximum tumor diameter of 1.5 cm or less, consisting of an active…
- Trial name
- MAeSTro-EXP (NCT06261190)
- Where
- 4 sites in South Korea
- Volunteers
- 499 people
- Sponsor
- National Cancer Center, Korea
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Papillary Thyroid Microcarcinoma
Active Surveillance of Papillary Thyroid Microcarcinoma
The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC).
- Trial name
- PMCAS (NCT02609685)
- Testing
- Active Surveillance
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Cedars-Sinai Medical Center
to Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm
a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS
To study if its is safe to reduce the amount of postoperative treatments in those patients, who have been operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm, and in whom…
- Trial name
- NCT06271044
- Testing
- With radioiodine treatment, With postoperative radioiodine treatment
- Volunteers
- 61 people
- Sponsor
- Helsinki University Central Hospital